Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection. (Posaconazole)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02020213|
Recruitment Status : Withdrawn
First Posted : December 24, 2013
Last Update Posted : December 12, 2014
|Condition or disease||Intervention/treatment||Phase|
|Clinical Infection||Drug: Posaconazole||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment|
|Study Start Date :||December 2013|
|Actual Primary Completion Date :||December 2014|
Posaconazole, per oral , 400 mg, bid , 8 weeks.
400 mg po bid for 8 weeks
Other Name: posanol
- clinical response [ Time Frame: per 2 weeks ]fever subsides (< 38 C) dyspnea improves ( evaluate by clinical doctors) CXR improves
- serum galactomannan level [ Time Frame: per 2 weeks ]follow the galactomannan level and check if it corresponds to clinical response or not.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02020213
|Study Director:||Sz-Rung Huang, Bachelar||Chief of Infection department,TCVGH Pu-Li branch|